Cancer Research The Future of Cancer Research: Science and Patient Impact Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roh, H.
Right arrow Articles by Drebin, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roh, H.
Right arrow Articles by Drebin, J. A.
[Cancer Research 60, 560-565, February 1, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

Down-Regulation of HER2/neu Expression Induces Apoptosis in Human Cancer Cells That Overexpress HER2/neu1

Haeri Roh, James Pippin and Jeffrey A. Drebin2

Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110

The HER2/neu oncogene is overexpressed in a significant fraction of human tumors; such overexpression is thought to play a role in the aberrant proliferation of cancer cells. The effects of HER2/neu-specific phosphorothioate antisense oligodeoxyribonucleotides on HER2/neu expression, tumor cell proliferation, and activation of apoptotic cell death pathways have been examined. Antisense treatment down-regulates HER2/neu expression in a dose-dependent and sequence-specific manner. HER2/neu antisense treatment specifically inhibits the growth of tumor lines that overexpress HER2/neu, but it has little effect on the growth of tumor cells that express low levels of HER2/neu. Down-regulation of HER2/neu expression is not only cytostatic, but it also results in the activation of apoptotic cell death pathways in cells that overexpress HER2/neu. These results suggest that, in addition to stimulating tumor cell proliferation, HER2/neu overexpression in cancer cells acts as an antiapoptotic cell survival factor.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
M. Provinciali, F. Papalini, F. Orlando, S. Pierpaoli, A. Donnini, P. Morazzoni, A. Riva, and A. Smorlesi
Effect of the Silybin-Phosphatidylcholine Complex (IdB 1016) on the Development of Mammary Tumors in HER-2/neu Transgenic Mice
Cancer Res., March 1, 2007; 67(5): 2022 - 2029.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-C. Wen, S.-A. Cheng, S.-P. Hsuen, Y.-L. Huang, Z.-K. Kuo, H.-F. Lee, C.-H. Kuo, J.-L. Du, and W.-B. Wang
SV40 T/t-Common Polypeptide Specifically Induces Apoptosis in Human Cancer Cells that Overexpress HER2/neu
Cancer Res., June 1, 2006; 66(11): 5847 - 5857.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y.-P. Lim, C. Y. Wong, L. L. Ooi, B. J. Druker, and R. J. Epstein
Selective Tyrosine Hyperphosphorylation of Cytoskeletal and Stress Proteins in Primary Human Breast Cancers: Implications for Adjuvant Use of Kinase-Inhibitory Drugs
Clin. Cancer Res., June 15, 2004; 10(12): 3980 - 3987.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. R. D. Quadros, F. Peruzzi, C. Kari, and U. Rodeck
Complex Regulation of Signal Transducers and Activators of Transcription 3 Activation in Normal and Malignant Keratinocytes
Cancer Res., June 1, 2004; 64(11): 3934 - 3939.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Shao, B. M. Evers, and H. Sheng
Prostaglandin E2 Synergistically Enhances Receptor Tyrosine Kinase-dependent Signaling System in Colon Cancer Cells
J. Biol. Chem., April 2, 2004; 279(14): 14287 - 14293.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Yang, K. Q. Cai, J. A. Thompson-Lanza, R. C. Bast Jr., and J. Liu
Inhibition of Breast and Ovarian Tumor Growth through Multiple Signaling Pathways by Using Retrovirus-mediated Small Interfering RNA against Her-2/neu Gene Expression
J. Biol. Chem., February 6, 2004; 279(6): 4339 - 4345.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. B. Schiffer, S. Gebhard, C. K. Heimerdinger, A. Heling, J. Hast, U. Wollscheid, B. Seliger, B. Tanner, S. Gilbert, T. Beckers, et al.
Switching Off HER-2/neu in a Tetracycline-Controlled Mouse Tumor Model Leads to Apoptosis and Tumor-Size-Dependent Remission
Cancer Res., November 1, 2003; 63(21): 7221 - 7231.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
G. Sithanandam, G. T. Smith, A. Masuda, T. Takahashi, L. M. Anderson, and L. W. Fornwald
Cell cycle activation in lung adenocarcinoma cells by the ErbB3/phosphatidylinositol 3-kinase/Akt pathway
Carcinogenesis, October 1, 2003; 24(10): 1581 - 1592.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. G. Barbacci, L. R. Pustilnik, A. M. K. Rossi, E. Emerson, P. E. Miller, B. P. Boscoe, E. D. Cox, K. K. Iwata, J. P. Jani, K. Provoncha, et al.
The Biological and Biochemical Effects of CP-654577, a Selective erbB2 Kinase Inhibitor, on Human Breast Cancer Cells
Cancer Res., August 1, 2003; 63(15): 4450 - 4459.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. Renard, L. Sonderbye, K. Ebbehoj, P. B. Rasmussen, K. Gregorius, T. Gottschalk, S. Mouritsen, A. Gautam, and D. R. Leach
HER-2 DNA and Protein Vaccines Containing Potent Th Cell Epitopes Induce Distinct Protective and Therapeutic Antitumor Responses in HER-2 Transgenic Mice
J. Immunol., August 1, 2003; 171(3): 1588 - 1595.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Asada, Y. Choi, M. Yamada, S.-C. Wang, M.-C. Hung, J. Qin, and M. Uesugi
External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator
PNAS, October 1, 2002; 99(20): 12747 - 12752.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. I. Spiridon, M.-A. Ghetie, J. Uhr, R. Marches, J.-L. Li, G.-L. Shen, and E. S. Vitetta
Targeting Multiple Her-2 Epitopes with Monoclonal Antibodies Results in Improved Antigrowth Activity of a Human Breast Cancer Cell Line in Vitro and in Vivo
Clin. Cancer Res., June 1, 2002; 8(6): 1720 - 1730.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. K. Scott, C. Marden, F. Xu, L. Kirk, and C. C. Benz
Transcriptional Repression of ErbB2 by Histone Deacetylase Inhibitors Detected by a Genomically Integrated ErbB2 Promoter-reporting Cell Screen
Mol. Cancer Ther., April 1, 2002; 1(6): 385 - 392.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
N. Normanno, M. Campiglio, A. De Luca, G. Somenzi, M. Maiello, F. Ciardiello, L. Gianni, D. S. Salomon, and S. Menard
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth
Ann. Onc., January 19, 2002; 13(1): 65 - 72.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. W. Rusnak, K. Lackey, K. Affleck, E. R. Wood, K. J. Alligood, N. Rhodes, B. R. Keith, D. M. Murray, W. B. Knight, R. J. Mullin, et al.
The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in Vitro and in Vivo
Mol. Cancer Ther., December 1, 2001; 1(2): 85 - 94.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Cuello, S. A. Ettenberg, A. S. Clark, M. M. Keane, R. H. Posner, M. M. Nau, P. A. Dennis, and S. Lipkowitz
Down-Regulation of the erbB-2 Receptor by Trastuzumab (Herceptin) Enhances Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated Apoptosis in Breast and Ovarian Cancer Cell Lines that Overexpress erbB-2
Cancer Res., June 1, 2001; 61(12): 4892 - 4900.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Liu, S. M. Edgerton, D. H. Moore II, and A. D. Thor
Measures of Cell Turnover (Proliferation and Apoptosis) and Their Association with Survival in Breast Cancer
Clin. Cancer Res., June 1, 2001; 7(6): 1716 - 1723.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. F. Symmans, M. D. Volm, R. L. Shapiro, A. B. Perkins, A. Y. Kim, S. Demaria, H. T. Yee, H. McMullen, R. Oratz, P. Klein, et al.
Paclitaxel-induced Apoptosis and Mitotic Arrest Assessed by Serial Fine-Needle Aspiration: Implications for Early Prediction of Breast Cancer Response to Neoadjuvant Treatment
Clin. Cancer Res., December 1, 2000; 6(12): 4610 - 4617.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
O. Tikhomirov and G. Carpenter
Caspase-dependent Cleavage of ErbB-2 by Geldanamycin and Staurosporin
J. Biol. Chem., August 31, 2001; 276(36): 33675 - 33680.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.